Randomized trial · people
Exenatide did not cut heavy drinking days in alcohol use disorder
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, weekly exenatide plus therapy did not reduce heavy drinking overall, though it changed brain responses to alcohol cues and showed a signal in people with obesity.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 127
- Published
- 2022
- Journal
- JCI Insight
What they tested
The team tested whether weekly exenatide lowers the number of heavy drinking days in people seeking treatment for alcohol use disorder.
How the study was done
A randomized, double-blind, placebo-controlled trial in 127 patients with alcohol use disorder. They received exenatide 2 mg or placebo (a dummy shot) under the skin once weekly for 26 weeks, on top of standard cognitive-behavioral therapy (talk therapy), and a subgroup had brain scans.

What they found
The main outcome, heavy drinking days, did not fall by a statistically significant amount with exenatide versus placebo. On fMRI brain scans, people on exenatide showed significantly weaker reactions to alcohol cues in the ventral striatum and septal area, regions linked to reward and addiction. SPECT scans showed less dopamine transporter availability with exenatide than with placebo. In an exploratory look at patients with obesity (BMI > 30 kg/m2), those on exenatide had significantly fewer heavy drinking days and drank less alcohol overall, and side effects were mostly in the gut.
What it doesn’t show
The trial missed its main goal in the full group. The brain scans covered only a subgroup, and the benefit in patients with obesity came from an exploratory analysis, so it is a lead rather than a confirmed result.
The paper
Klausen et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022.
The compound
More studies on Exenatide
- Exenatide: no cognitive benefit in mild cognitive impairmentRandomized trial · people · 2024
- Exenatide: lower intracranial pressure in IIH over 12 weeksRandomized trial · people · 2023
- Exenatide: 29.2% spontaneous pregnancy vs 14.7% on metformin in PCOSRandomized trial · people · 2022
- Exenatide plus dapagliflozin: UACR fell 39.6% vs 11.0% on placeboRandomized trial · people · 2021
- Exenatide, alone or with dapagliflozin, improved blood sugar in PCOSRandomized trial · people · 2021
- Exenatide ER: 0.9% HbA1c drop vs 1.5% with semaglutide in SUSTAIN 3Randomized trial · people · 2018
- Every study on Exenatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.